Patents by Inventor Nathalie Dunkel

Nathalie Dunkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preparation of isolated agonist anti-EDAR monoclonal antibodies
    Patent number: 8741297
    Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: June 3, 2014
    Assignees: Edimer Pharmaceuticals, Inc., Universite de Lausanne
    Inventors: Pascal Schneider, Nathalie Dunkel, Stéphane Demotz
  • PREPARATION OF ISOLATED AGONIST ANTI-EDAR MONOCLONAL ANTIBODIES
    Publication number: 20130273046
    Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.
    Type: Application
    Filed: March 8, 2013
    Publication date: October 17, 2013
    Applicants: UNIVERSITE DE LAUSANNE, EDIMER PHARMACEUTICALS, INC.
    Inventors: Pascal Schneider, Nathalie Dunkel, Stéphane Demotz
  • Preparation of isolated agonist anti-EDAR monoclonal antibodies
    Patent number: 8496937
    Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: July 30, 2013
    Assignees: Edimer Pharmaceuticals, Inc., Universite de Lausanne
    Inventors: Pascal Schneider, Nathalie Dunkel, Stephane Demotz
  • PREPARATION OF ISOLATED AGONIST ANTI-EDAR MONOCLONAL ANTIBODIES
    Publication number: 20120192296
    Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.
    Type: Application
    Filed: March 30, 2010
    Publication date: July 26, 2012
    Applicants: Universite de Lausanne, Edimer Biotech S.A.
    Inventors: Pascal Schneider, Nathalie Dunkel, Stephane Demotz